Pralidoxime Chloride

☝ 点击上方 一键预约 ☝   最新最热的医药健康新闻政策短缺药纳入集采名单，是国家重视短缺药的保障供应的重要举措。近年来，部分急救药品价格跳涨的事情时而出现。氯解磷定注射液（2ml:0.5g*1）的中标价曾从4.61元上涨至178元；西地兰（2ml:0.4mg*1）中标价曾从11元上涨至89元。价格与用量，是影响短缺药企业生产供应的决定性因素。造成短缺的原因有经济社会成本过高、原料生产成本上涨、人为垄断原材料、招采政策的更新迟缓等等一些难以控制的因素，短缺药这一“老大难”问题治理，亟需求变！01逐步纳入国家集采和地方集采政策治理翻开新篇章在刚结束的第九批国采中，用于催产的缩宫素注射剂等5种短缺药品和急抢救药品，均在品种目录覆盖范围内。无独有偶，10月27日，广州公共资源交易中心发布了《易短缺和急抢救药联盟集中带量采购文件》征求意见稿，将短缺药纳入集采。包括有酚妥拉明注射剂、苯巴比妥注射剂、呋塞米等18个临床必需易短缺类、急抢救类等化学药品和治疗用生物制品纳入集采范围。来源：《易短缺和急抢救药联盟集中带量采购文件》短缺药集采聚焦保供稳价。每个品种组别分别设置了最高有效申报价格。其中，最高有效申报价格和各产品的实际交易价格两者之间的低值简称为“P0”，各产品的申报价不高于P0的，视为有效报价。有专家学者表示，并非所有短缺药品种都适合集采，需要分析具体短缺的原因，对症下药。只有“真短缺”的药品才适合纳入集采，向企业明确需求量，提高行业集中度，利用成本规模提高利润，同时保障供应。02价稳量多，提振短缺药市场预期氨茶碱注射液市场销售额涨势厉害，个别品规的价格上浮较大。中康开思数据库显示，2023上半年氨茶碱注射液品种的等级医院销售同比增长165%，其中金耀药业的氨茶碱注射液（10ml:0.25mg*5）价格在上调明显，市场增长源于单价的上涨。来源：开思数据地高辛注射液等级医院市场上半年同比增长47%，品规单价是下调趋势。例如，西南药业的地高辛注射液（2ml:0.5mg*2）的单价从2021年底开始下调，2023年上半年销售额同比增长45%，是由销售量上升驱动。来源：开思数据药品是特殊商品，药品市场也是特殊市场，关系到民众的生命健康。解决药品短缺保供稳价问题，坚持“加强监测、分级应对、分类管理、清单制度、统筹联动、强化监管、保障供应”的原则，在运用市场机制、探索集中带量采购的同时，加强政府直接干预，加大市场监测调节，强化行政执法监管。（来源:新康界  作者:牛果）药闻康策新媒体矩阵微信公众号点击下方  一键关注  【免责声明】1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、收藏、点赞、点在看

Jobs that will be affected at AktiVax run the gamut from patent prosecution and purchasing agents to engineers, technicians, quality control microbiologists and human resources executives. Despite scoring a number of federal contracts in recent years, it’s lights out for government-backed rescue autoinjector maker AktiVax. Late last month, AktiVax, also known as Aktiv Pharma Group, informed the state of Colorado that “the company must shut down substantially all of its operations,” citing “unexpected circumstances.” In turn, the company is mothballing three manufacturing facilities and laying off around 70 employees. The plant closures and layoffs are set to affect a facility in Broomfield, Colorado, plus two sites in Fort Collins, according to a letter sent to a state official. The “entire plants” are to be closed, and AktiVax expects the action will be “permanent.” Jobs that will be affected run the gamut from patent prosecution and purchasing agents to engineers, technicians, quality control microbiologists and human resources executives. AktiVax’s business primarily revolves around its autoinjector ARAI, which the company says is the only autoinjector with single-hand, single-step activation. AktiVax has won several federal contracts in recent years, with the Denver Business Journal noting the company has publicly announced more than $275 million in government pacts since 2018. Back in the spring of 2020, for instance, AktiVax was awarded $24.5 million for a U.S. government project to develop an autoinjector treatment for exposure to nerve agents. The five-year pact put AktiVax on deck to develop and win approval for a scopolamine hydrobromide autoinjector for several nerve agents. In a press release at the time, the company noted emergency nerve agent treatment was well suited to autoinjectors given the speediness and ease of use of the delivery format. Meanwhile, in 2018, the Biomedical Advanced Research and Development Authority granted AktiVax $15.5 million to develop a manufacturing-approved production line for the ARAI autoinjector. The company notes it completed that project in Dececember 2019. AktiVax’s most recent contract appears to be from October 2022, the month the company won a $45 million contract to supply pralidoxime chloride autoinjectors for the Strategic National Stockpile. That deal, also focused on nerve agent antidotes, was set to reach a value of upward of $220 million over seven years. At the time, the company said it was also working with another unnamed drugmaker to develop a reconstitution autoinjector for a long-acting formulation of the popular opioid overdose reversal agent naloxone.